66. IgA腎症 IgA nephropathy Clinical trials / Disease details
臨床試験数 : 275 / 薬物数 : 258 - (DrugBank : 82) / 標的遺伝子数 : 36 - 標的パスウェイ数 : 140
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04342325 (ClinicalTrials.gov) | June 15, 2020 | 8/4/2020 | The Clinical Trial of ADR-001 for IgA Nephropathy | Open-label, Multiple-center, Dose-Escalation Study to Evaluate the Safety and Tolerability of ADR-001 for the Treatment for Immunoglobulin A (IgA) Nephropathy | Glomerulonephritis , IGA | Biological: infusion of ADR-001 (Mesenchymal stem cell) | Nagoya University | Rohto Pharmaceutical Co., Ltd. | Active, not recruiting | 20 Years | N/A | All | 9 | Phase 1 | Japan |